Steroid-Free Chemotherapy Decreases the Risk of Hepatitis Flare-up in Hepatitis B Virus Carriers With NonHodgkin's Lymphoma
To the Editor:
Reactivation of hepatitis B virus (HBV) has frequently been observed during the chemotherapy of HBV carriers with non-Hodgkin's lymphoma (NHL).'.* This issue is particularly important in HBV endemic areas around the world, in which the HBV carrier rate of the population may be as high as 15% to 20%.
Several lines of evidence suggest that glucocorticoids, ingredients of most first-line chemotherapy for NHL, are important predisposing factors to HBV reactivation: (1) HBV carriers with other solid tumors, who are usually treated by steroid-free chemotherapy, have rarely experienced HBV reactivation. (2) A retrospective Japanese study, comparing steroid-containing versus steroid-free regimens in the treatment of HBV carriers with hematological malignancies, reported a significant higher risk of hepatitis flare-up in the former group.' (3) HBV DNA was found to contain a glucocorticoid-responsive element? (4) Glucocorticoids specifically activate HBV gene expression in cultured human hepatoma cells which were transfected by HBV genomes. ' Between January I988 and December 1994, a total of 38 lymphoma patients, whose serum HBsAg (HBV surface antigen) had been prospectively examined to be positive, were treated by a standard CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisolone) regimen in our institutions. Eighteen patients (47.4%) developed hepatitis during chemotherapy. Among them, 9 patients (23.2%) had serum alanine aminotransferase >500 IUL, while 3 (7.9%) died of fulminant hepatitis and another 3 died of progressive lymphoma.
During the same period of time, 12 lymphoma patients with positive serum HBsAg were prospectively treated by steroid-free chemotherapy. ACE (doxorubicin 40 mg/m2, intravenously [IV], D1 ; cyclophosphamide 650 mg/m*, IV, Dl; VP-16 55 mg/mz, IV, D1-3), VIM (VP-16 100 mglm', IV, D1,3,5; ifosfamide 1.0 gm/m2, IV, Dl-5; methotrexate 30 mg/m', IV, D1,5), and ACO (doxorubicin 55 mg/ m*, IV, Dl; cyclophosphamide 750 mg/m2, IV, Dl; vincristine 1.4 mg/m2, IV, Dl) were used in 7.3, and 2 patients of diffuse aggressive lymphoma, respectively. Only I (8.3%) of these 12 patients developed clinical hepatitis during chemotherapy ( P < .05). Ten patients (83.3%) achieved complete remission, and 8 of them remain disease free at this report with a median follow-up of 34 months.
Our data suggest that steroid-free chemotherapy reduces the risk of hepatitis flare-up in HBV carriers. A larger-scale prospective study comparing steroids-containing and steroids-free chemotherapies in HBV carriers with NHL is mandatory. 
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